Intra-Cellular Therapies Inc

NASDAQ:ITCI

72.37

+0.37 (+0.51%)

6:45:40 PM EDT: $73.00 +0.63 (+0.87%)

Market Cap (Intraday)	7.01B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	68.27

See more stats

Estimates Current Quarter

Revenue	$140.91 Million
Adjusted EPS	-$0.33

See more estimates

10-Day MA	$71.17
50-Day MA	$69.30
200-Day MA	$62.01

See more pivots

Intra-Cellular Therapies Inc Stock, NASDAQ:ITCI

430 East 29th Street, Suite 900, New York, New York 10016

United States of America

Phone: +1.464.440.9333

Number of Employees: 610

http://www.intracellulartherapies.com

Description

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firmÃ¢â?¬â?¢s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.